GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qyuns Therapeutics Co Ltd (HKSE:02509) » Definitions » Preferred Stock

Qyuns Therapeutics Co (HKSE:02509) Preferred Stock : HK$0.0 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Qyuns Therapeutics Co Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Qyuns Therapeutics Co's preferred stock for the quarter that ended in Jun. 2024 was HK$0.0 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Qyuns Therapeutics Co's Enterprise Value for the quarter that ended in Jun. 2024 was HK$3,919.6 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Qyuns Therapeutics Co's Book Value per Share for the quarter that ended in Jun. 2024 was HK$1.78.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Qyuns Therapeutics Co's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was HK$0.00.


Qyuns Therapeutics Co Preferred Stock Historical Data

The historical data trend for Qyuns Therapeutics Co's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qyuns Therapeutics Co Preferred Stock Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Preferred Stock
- - - -

Qyuns Therapeutics Co Quarterly Data
Dec21 Dec22 Sep23 Dec23 Jun24 Dec24
Preferred Stock Get a 7-Day Free Trial - - - - -

Qyuns Therapeutics Co Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Qyuns Therapeutics Co  (HKSE:02509) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Qyuns Therapeutics Co's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Qyuns Therapeutics Co's Book Value per Share for the quarter that ended in Jun. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Qyuns Therapeutics Co's Earnings per Share (Diluted) (EPS) for the three months ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qyuns Therapeutics Co Preferred Stock Related Terms

Thank you for viewing the detailed overview of Qyuns Therapeutics Co's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Qyuns Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline.
Executives
Tai Zhou Yi Yao Cheng Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Jian Xin Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Hang Zhou Zhong Mei Hua Dong Zhi Yao You Xian Gong Si 2101 Beneficial owner
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Ji Shu Chan Ye Tou Zi Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Qu Hua Yin Jin Rong Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Yuan Da Hua Chuang Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Hua Dong Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Qiu Jiwan
Xu Qiu
Hangzhou Quanyi Investment Management Partnership (general Partnership)
Yu Guo'an
Zhu Jing
Taizhou Xinfu Tongxin Enterprise Management Partnership (limited Partnership)
Sheng Xi Tai

Qyuns Therapeutics Co Headlines

No Headlines